MEMELIN 25mg tablets medication leaflet

L02BG06 exemestane • Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors

Exemestane is a medication used in the treatment of hormone-dependent breast cancer in postmenopausal women. It belongs to the class of aromatase inhibitors and works by reducing estrogen levels in the body, which slows or stops the growth of tumors that require estrogen to grow.

It is indicated for the treatment of early-stage breast cancer after tamoxifen therapy or for advanced or metastatic breast cancer. Exemestane is taken orally in tablet form, usually once daily after a meal.

Side effects may include hot flashes, fatigue, joint or muscle pain, insomnia, nausea, osteoporosis or decreased bone density, and excessive sweating. Rarely, allergic reactions or liver disorders may occur.

Exemestane is contraindicated in premenopausal women, during pregnancy, or while breastfeeding. It is important to take the medication as prescribed by a doctor, and patients should be monitored regularly to assess effectiveness and potential side effects.

General data about MEMELIN 25mg

Substance: exemestane

Date of last drug list: 01-03-2017

Commercial code: W63313005

Concentration: 25mg

Pharmaceutical form: tablets

Quantity: 90

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: EIRGEN PHARMA LTD. - IRLANDA

Holder: STADA HEMOFARM S.R.L. - ROMANIA

Number: 11053/2018/04

Shelf life: 3 years

Pharmaceutical forms available for exemestane

Other substances similar to exemestane